Try our beta test site
12 studies found for:    lymphoma OR CLL | TGR-1202
Show Display Options
Rank Status Study
1 Recruiting A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: TGR-1202;   Drug: Ibrutinib
2 Recruiting Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: TGR-1202
3 Active, not recruiting TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: TGR-1202 + Obinutuzumab + Chlorambucil
4 Active, not recruiting Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
Condition: Hodgkin's Lymphoma
Intervention: Drug: TGR-1202 + brentuximab vedotin
5 Recruiting Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Pembrolizumab;   Drug: TGR-1202;   Biological: ublituximab
6 Recruiting Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202
7 Recruiting TGR-1202 and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: PI3K-delta Inhibitor TGR-1202
8 Recruiting Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
Conditions: Hodgkin Disease;   Lymphoma, Non-hodgkin
Interventions: Drug: Carfilzomib;   Drug: TGR-1202
9 Recruiting Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: Obinutuzumab;   Biological: Ublituximab;   Drug: TGR-1202;   Drug: Chlorambucil
10 Recruiting Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Non-Hodgkin's Lymphoma
Interventions: Drug: Ublituximab + TGR-1202;   Drug: Ublituximab + TGR-1202 + ibrutinib;   Drug: Ublituximab + TGR-1202 + bendamustine
11 Active, not recruiting Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Peripheral T-Cell Lymphoma;   Hodgkin's Lymphoma
Intervention: Drug: TGR-1202
12 Recruiting An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: ublituximab;   Drug: TGR-1202

Study has passed its completion date and status has not been verified in more than two years.